These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38243208)

  • 1. Characteristics of patients with schizophrenia switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M): a systematic review.
    Li Q; Li X; Ye C; Jia M; Si T
    BMC Psychiatry; 2024 Jan; 24(1):57. PubMed ID: 38243208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis.
    Li Q; Li X; Ye C; Jia M; Si T
    CNS Drugs; 2023 Aug; 37(8):695-713. PubMed ID: 37490267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia.
    Li X; Ye C; Zhang W; Jia M; Wang G
    CNS Drugs; 2024 Jan; 38(1):55-65. PubMed ID: 38190077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
    Zhdanava M; Lin D; Lafeuille MH; Ghelerter I; Morrison L; Lefebvre P; Joshi K
    Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
    Mathews M; Pei H; Savitz A; Nuamah I; Hough D; Alphs L; Gopal S
    Clin Drug Investig; 2018 Aug; 38(8):695-702. PubMed ID: 29882073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia.
    El Khoury AC; Pilon D; Morrison L; Shak N; Vermette-Laforme M; Amos TB; Kim E; Lefebvre P
    Curr Med Res Opin; 2019 Mar; 35(3):395-405. PubMed ID: 30526125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
    Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
    Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China.
    Liu J; Wang Q; Su L; Yang L; Zou L; Bai L
    BMC Psychiatry; 2022 Feb; 22(1):95. PubMed ID: 35135512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Effect With Paliperidone Palmitate Compared With Oral Antipsychotics in Black/African American Patients With Schizophrenia and a History of Criminal Justice System Involvement: A Post Hoc Analysis of the PRIDE Study.
    Bell Lynum KS; Henderson DC; Wright HJ; Gogate JP; Kim E
    J Clin Psychiatry; 2021 Feb; 82(2):. PubMed ID: 33988924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US.
    Manjelievskaia J; Amos TB; El Khoury AC; Vlahiotis A; Cole A; Juneau P
    J Med Econ; 2018 Dec; 21(12):1221-1229. PubMed ID: 30238806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia.
    Hargarter L; Bergmans P; Cherubin P; Keim S; Conca A; Serrano-Blanco A; Bitter I; Bilanakis N; Schreiner A
    Expert Opin Pharmacother; 2016 Jun; 17(8):1043-53. PubMed ID: 27042990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia.
    Brown B; Turkoz I; Mancevski B; Mathews M
    Early Interv Psychiatry; 2020 Aug; 14(4):428-438. PubMed ID: 31515972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A post hoc analysis on hospitalization risk in Asian patients with schizophrenia switching to once-monthly paliperidone palmitate from oral antipsychotics.
    Li N; Zhuo JM; Turkoz I; Mathews M; Feng Y; Tan W
    Expert Opin Pharmacother; 2019 Nov; 20(16):2033-2039. PubMed ID: 31393186
    [No Abstract]   [Full Text] [Related]  

  • 14. Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization.
    El Khoury A; Patel C; Huang A; Wang L; Bashyal R
    Curr Med Res Opin; 2019 Dec; 35(12):2159-2168. PubMed ID: 31366251
    [No Abstract]   [Full Text] [Related]  

  • 15. Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation.
    Dickson MC; Nguyen MM; Patel C; Grabich SC; Benson C; Cothran T; Skrepnek GH
    Adv Ther; 2023 Jan; 40(1):349-366. PubMed ID: 36348142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety.
    Si T; Zhuo J; Turkoz I; Mathews M; Tan W; Feng Y
    Expert Opin Pharmacother; 2017 Dec; 18(17):1799-1809. PubMed ID: 29141463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
    Patel C; El Khoury A; Huang A; Wang L; Baser O; Joshi K
    Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate.
    Lin D; Pilon D; Zhdanava M; Joshi K; Lafeuille MH; Côté-Sergent A; Vermette-Laforme M; Lefebvre P
    Curr Med Res Opin; 2021 Apr; 37(4):675-683. PubMed ID: 33507838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR).
    Schreiner A; Hargarter L; Hitschfield K; Lee JI; Lenskaya I; Sulaiman AH; Diels J;
    Curr Med Res Opin; 2014 Jul; 30(7):1279-89. PubMed ID: 24597755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.
    Pilon D; Muser E; Lefebvre P; Kamstra R; Emond B; Joshi K
    BMC Psychiatry; 2017 Jun; 17(1):207. PubMed ID: 28576133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.